Telaprevir vs Boceprevir in First- and Second-Line Settings
[This is a repost of the table in #msg-52978824 where the Telaprevir phase-2 PROVE-3 study has been replaced by the much larger phase-3 REALIZE study.]
In the Telaprevir REALIZE study, the entries in the table below refer to the non-null-responder subset rather than the full dataset because the non-null-responder subgroup is the patient group that was treated in the Boceprevir RESPOND-2 study (#msg-54316658).
On null responder definition - there's more acceptance and I think it will grow, for the “early null responder” who is characterized by <1 log drop in HCV RNA levels at week 4 according to data from the IDEAL study.